Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2025-02-13 00:00:00 ET · period of report 2025-02-12 · accession 0001933414-25-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-13 | 2025-02-12 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $1.08 | +6,348 | 164.5K | +4% | +$6,856 |
| D | 2025-02-13 | 2025-02-12 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.00 | -6,348 | 122.2K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-12 | M | A | 6,348 | $1.08 | 164,520 | D | — | — | |
| 2 | Derivative | Stock Option | 2025-02-12 | M | D | 6,348 | $0.00 | 122,229 | D | $1.08 · — to 2032-07-11 | 6,348 Common Stock | (F1) The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. |